Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2

Ann Hematol. 1991 Feb;62(1):25-31. doi: 10.1007/BF01714980.

Abstract

This study was designed to investigate acute effects of various doses of the cytokines IFN-alpha, IFN-gamma, Interleukin 2 and tumor necrosis factor alpha on white blood cell differential counts. Before initiation of phase II trials, a dose-determination phase was performed, where three different dose levels of each cytokine were applied as a single dose. White blood cell differential counts were assessed immediately before and 2, 12, 24, 48 and 168 h after injection. Patients enrolled suffered from metastatic cancer or chronic active hepatitis. In addition, IFN-alpha was administered to five healthy volunteers. Results indicate that cytokines cause rapid and transient changes in the numbers of leukocyte subsets. Hematologic changes were cell-type- and cytokine-specific: transient lymphopenia was observed after administration of all four cytokines, reaching a nadir 12 to 24 h after subcutaneous injection. Administration of TNF-alpha and IFN-gamma also caused transient monocytopenia. Neutrophilia developed after administration of Interleukin 2, IFN-alpha and TNF-alpha. We conclude that cytokines play a key role in the regulation of peripheral blood cell traffic by their capacity to influence homing patterns of peripheral blood leukocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Granulocytes / pathology
  • Hepatitis, Chronic / pathology
  • Hepatitis, Chronic / therapy
  • Humans
  • Interferon Type I / adverse effects*
  • Interferon Type I / therapeutic use
  • Interferon-gamma / adverse effects*
  • Interferon-gamma / therapeutic use
  • Interleukin-2 / adverse effects*
  • Interleukin-2 / therapeutic use
  • Kinetics
  • Leukocyte Count
  • Leukocytes / pathology*
  • Lymphocytes / pathology
  • Male
  • Monocytes / pathology
  • Neoplasms / pathology
  • Neoplasms / therapy
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Tumor Necrosis Factor-alpha / adverse effects*
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Interferon Type I
  • Interleukin-2
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma